385 related articles for article (PubMed ID: 33526874)
21. The Morphological Spectrum of Papillary Renal Cell Carcinoma and Prevalence of Provisional/Emerging Renal Tumor Entities with Papillary Growth.
Lobo J; Ohashi R; Helmchen BM; Rupp NJ; Rüschoff JH; Moch H
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680535
[TBL] [Abstract][Full Text] [Related]
22. What's new in the WHO 2022 classification of kidney tumours?
Alaghehbandan R; Siadat F; Trpkov K
Pathologica; 2022 Feb; 115(1):8-22. PubMed ID: 36645398
[TBL] [Abstract][Full Text] [Related]
23. Atrophic Kidney Like Lesion: A Provisional Entity With Brief Review of Literature.
Narwal A; Kaushal S; Nakra T; Sharma MC; Kumar M
Int J Surg Pathol; 2022 Sep; 30(6):652-657. PubMed ID: 35037508
[TBL] [Abstract][Full Text] [Related]
24. TSC/MTOR -associated Eosinophilic Renal Tumors Exhibit a Heterogeneous Clinicopathologic Spectrum : A Targeted Next-generation Sequencing and Gene Expression Profiling Study.
Xia QY; Wang XT; Zhao M; He HY; Fang R; Ye SB; Li R; Wang X; Zhang RS; Lu ZF; Ma HH; Wang ZY; Rao Q
Am J Surg Pathol; 2022 Nov; 46(11):1562-1576. PubMed ID: 35980750
[TBL] [Abstract][Full Text] [Related]
25. Are Renal Cell Carcinoma with Fibromyomatous Stroma (RCC-FMS) and Thyroid-like Follicular Carcinoma of the Kidney (TLFCK) Really Independent Variants?
Stanca S; Boldrini L; Erba PA; Faviana P
Diagnostics (Basel); 2022 Dec; 13(1):. PubMed ID: 36611378
[TBL] [Abstract][Full Text] [Related]
26. Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting.
Kapur P; Brugarolas J; Trpkov K
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627070
[TBL] [Abstract][Full Text] [Related]
27. Emerging Entities in Renal Neoplasia.
Mehra R; Smith SC; Divatia M; Amin MB
Surg Pathol Clin; 2015 Dec; 8(4):623-56. PubMed ID: 26612218
[TBL] [Abstract][Full Text] [Related]
28. Renal Cell Carcinoma With Fibromyomatous Stroma: A New Case.
Haouane MA; Hajji F; Ghoundale O; Azami MA
Cureus; 2022 Dec; 14(12):e32238. PubMed ID: 36620787
[TBL] [Abstract][Full Text] [Related]
29. Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review.
Cimadamore A; Cheng L; Scarpelli M; Massari F; Mollica V; Santoni M; Lopez-Beltran A; Montironi R; Moch H
Transl Androl Urol; 2021 Mar; 10(3):1506-1520. PubMed ID: 33850785
[TBL] [Abstract][Full Text] [Related]
30. The WHO 2022 Classification of Renal Neoplasms (5th Edition): Salient Updates.
Goswami PR; Singh G; Patel T; Dave R
Cureus; 2024 Apr; 16(4):e58470. PubMed ID: 38765391
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic Biomarkers in Renal Cell Tumors According to the Latest WHO Classification: A Focus on Selected New Entities.
Sanguedolce F; Mazzucchelli R; Falagario UG; Cormio A; Zanelli M; Palicelli A; Zizzo M; Eccher A; Brunelli M; Galosi AB; Carrieri G; Cormio L
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791935
[TBL] [Abstract][Full Text] [Related]
32. Low grade oncocytic tumors of the kidney: a clinically relevant approach for the workup and accurate diagnosis.
Amin MB; McKenney JK; Martignoni G; Campbell SC; Pal S; Tickoo SK
Mod Pathol; 2022 Oct; 35(10):1306-1316. PubMed ID: 35896615
[TBL] [Abstract][Full Text] [Related]
33. [Eosinophilic, solid, and cystic renal cell carcinoma (ESC-RCC)].
Hartmann A; Agaimy A
Pathologe; 2021 Nov; 42(6):565-570. PubMed ID: 34550432
[TBL] [Abstract][Full Text] [Related]
34. Renal cell carcinoma with leiomyomatous stroma: a review of an emerging entity distinct from clear cell conventional renal cell carcinoma.
Yeh YA; Constantinescu M; Chaudoir C; Tanner A; Serkin F; Yu X; Fazili T; Lurie AA
Am J Clin Exp Urol; 2019; 7(5):321-326. PubMed ID: 31763363
[TBL] [Abstract][Full Text] [Related]
35.
Wangsiricharoen S; Zhong M; Ranganathan S; Matoso A; Argani P
Int J Surg Pathol; 2021 Oct; 29(7):808-814. PubMed ID: 33729862
[TBL] [Abstract][Full Text] [Related]
36. Algorithm-Based Approach to the Histological Routine Diagnosis of Renal Oncocytic Tumors in Core Biopsy Specimens.
Manini C; Imaz I; de Larrinoa AF; López JI
Curr Urol Rep; 2022 Nov; 23(11):327-333. PubMed ID: 36169870
[TBL] [Abstract][Full Text] [Related]
37. Mutated ASXL1 upregulates mTOR expression in renal cell carcinoma with fibromyomatous stroma.
Liu Y; Zhou L; Xu H; Gu Y; Dong L; Yang X; Wang C
Virchows Arch; 2023 Dec; ():. PubMed ID: 38102390
[TBL] [Abstract][Full Text] [Related]
38. Recurrent CYP2A6 gene mutation in biphasic hyalinizing psammomatous renal cell carcinoma: Additional support of three cases.
Ding X; Zhang W; Yu W; Li Y; Shao G; Zhang L; Zhao RC; Li X
Pathol Res Pract; 2023 May; 245():154468. PubMed ID: 37104959
[TBL] [Abstract][Full Text] [Related]
39. ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217.
Kuroda N; Trpkov K; Gao Y; Tretiakova M; Liu YJ; Ulamec M; Takeuchi K; Agaimy A; Przybycin C; Magi-Galluzzi C; Fushimi S; Kojima F; Sibony M; Hang JF; Pan CC; Yilmaz A; Siadat F; Sugawara E; Just PA; Ptakova N; Hes O
Mod Pathol; 2020 Dec; 33(12):2564-2579. PubMed ID: 32467651
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic and Molecular Pathology of Collecting Duct Carcinoma and Related Renal Cell Carcinomas.
Seo AN; Yoon G; Ro JY
Adv Anat Pathol; 2017 Mar; 24(2):65-77. PubMed ID: 28181950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
